LY4066434. + Cetuximab + Nab paclitaxel + Gemcitabine + Oxaliplatin + Leucovorin + Irinotecan + 5Fluorouracil + Carboplatin + Cisplatin + Pemetrexed + Pembrolizumab
Phase 1Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatic Ductal Adenocarcinoma
Conditions
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
Trial Timeline
Oct 21, 2024 → Jan 1, 2030
NCT ID
NCT06607185About LY4066434. + Cetuximab + Nab paclitaxel + Gemcitabine + Oxaliplatin + Leucovorin + Irinotecan + 5Fluorouracil + Carboplatin + Cisplatin + Pemetrexed + Pembrolizumab
LY4066434. + Cetuximab + Nab paclitaxel + Gemcitabine + Oxaliplatin + Leucovorin + Irinotecan + 5Fluorouracil + Carboplatin + Cisplatin + Pemetrexed + Pembrolizumab is a phase 1 stage product being developed by Eli Lilly for Pancreatic Ductal Adenocarcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT06607185. Target conditions include Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06607185 | Phase 1 | Active |
Competing Products
20 competing products in Pancreatic Ductal Adenocarcinoma